Mesenchymal Stem Cell-Derived Exosomes as a Neuroprotective and Neurorestorative Treatment Strategy for Traumatic Brain Injury

Successful transition of exosomes into clinical use as an early treatment for TBI.

Value Proposition

Mesenchymal stem cell (MSC)-derived exosomes are a new and potentially valuable therapeutic strategy for TBI. MSC-derived exosomes will be a high impact treatment strategy for TBI in both civilian and military sectors. Exosomes are easy to administer, have low immunogenicity, and cross the blood brain barrier.

Competitive Advantage

  • • Even when given 9 hours following TBI, MSC-derived exosomes demonstrate comparable efficacy to valproic acid (VPA) that was administered 1 hour following injury.

    • Exosomes can be isolated, purified, freeze-dried, and preserved (similar to other FDA-approved liposome therapies) to make them shelf-stable, which is logistically attractive for austere settings.

    • The rapid uptake of exosomes has been shown to result in immediate immune modulation, regeneration and promotion, and pathogen suppression by regulating neural cells.

    • In addition to therapeutic effects in TBI, MSC-derived exosomes have demonstrated attenuation of cardiovascular ischemia-reperfusion, sepsis, and acute kidney, liver, lung, and intestinal injuries.

Unique Features

  • Comparable efficacy to valproic acid (VPA)

  • Can be preserved to make them shelf-stable

  • Logistically attractive for austere settings

  • Results in immediate immune modulation, regeneration and promotion, and pathogen suppression by regulating neural cells

  • Demonstrated therapeutic effects in multiple illnesses including sepsis, kidney, liver, lung, and intestinal injuries

Licensed These products have established agreements with companies and/or manufacturers.

Licensing Information
NeurExoSciences in 2019

Principal Investigators
Hasan Alam, MD
Aaron Williams, MD
Benjamin Buller, PhD

Intellectual Property
Invention Disclosure # 2018-334
Patent Applications Submitted

Solution Sheet
Download Solution Sheet (PDF)

Image credit Shutterstock

MARKET OPPORTUNITY
Currently, no pharmacologic agents exist that are able to reduce the mortality associated with TBI, and improve neurologic outcomes following injury. The protective effects of exosomes are rapid and can be achieved in the absence of additional treatment or fluid resuscitation, making it very appealing as a pre-hospital treatment during the Golden Hours.

NeuroTrauma Sciences, LLC (NTS), NeurExoSciences, LLC with an exclusive license to the technology.

Contact NeuroExoSciences for more information about investment and partnership opportunities.

Funding History

$110,570 in non-dilutive funding

  • 2018 $110,570 Massey Grand Challenge

  • Substantial departmental, school and center based support

Funding Organizations

Publications

None at this time

LicensedKate Murphy